Table 2.

Two-way sensitivity analysis of DMOAD pain relief and suspended progression

Suspended Progression	Pain Relief	Treatment Strategy	Avg. QALE	Avg. Cost	ICER	Proportion of Cohort Receiving Primary TKR
50%	Base Case 30% 15% overall‡	Standard of Care*	14.21	$115,800		52.37%
		SoC + DMOADs**	14.25	$118,100	$57,500	44.35%
	40% 20% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.28	$118,000	$31,400	44.34%
	50% 25% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.32	$118,000	$20,000	44.33%
60%	30% 18% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.26	$118,400	$52,000	42.82%
	40% 24% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.30	$118,300	$27,800	42.82%
	50% 30% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.35	$118,200	$17,100	42.83%
70%	30% 21% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.28	$118,600	$40,000	41.31%
	40% 28% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.33	$118,600	$23,300	41.31%
	50% 35% overall	Standard of Care	14.21	$115,800		52.37%
		SoC + DMOADs	14.38	$118,500	$15,900	41.31%

^*Standard of care sequence: conservative pain management (NSAIDs, acetaminophen, physical therapy), corticosteroid injections, primary TKR, revision TKR

^**Standard of care + DMOADs sequence: conservative pain management, DMOADs, corticosteroid injections, primary TKR, revision TKR

^‡Overall pain relief is calculated as (% pain relief given suspended progression) × (% suspended progression); the top row of this table corresponds with 30% pain relief given suspended progression, 50% suspended progression, and thus 15% overall pain relief.

Abbreviations: ICER, incremental cost-effectiveness ratio; TKR, total knee replacement; SoC, standard of care